LC-MS determination and bioavailability study of loperamide hydrochloride after oral administration of loperamide capsule in human volunteers

Jin Hee Yu, Hye Jin Kim, Sibeum Lee, Sung Joo Hwang, Won Kim, Cheol Jin Moon

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The purpose of the present study was to develop a standard protocol for loperamide hydrochloride bioequivalence testing. For this purpose, a simple rapid and selective LC-MS method utilizing a single quadrupole mass spectrometer was developed and validated for the determination of loperamide hydrochloride in human plasma, and we followed this with a bioavailability study. Methyl tert-butylether (MTBE) was used to extract loperamide hydrochloride and ketoconazole (internal standard (IS)) from an alkaline plasma sample. LC separation was performed on a Zorbax RX C 18 column (5 μm, 2.1 mm × 150 mm) using acetonitrile-water-formic acid (50:50:0.1 (v/v)) as a mobile phase. The retention times of loperamide hydrochloride and IS were 1.2 and 0.8 min, respectively. Quadrupole MS detection was by monitoring at m/z 477 (M + 1) corresponding to loperamide hydrochloride and at m/z 531 (M + 1) for IS. The described assay method showed acceptable precision, accuracy, linearity, stability, and specificity. The bioavailability of loperamide hydrochloride was evaluated in eight healthy male volunteers. The following pharmacokinetic parameters were elucidated after administering a single dose of four 2 mg capsules of loperamide: the area under the plasma concentration versus time curve from time 0 to 72 h (AUC 72 h) 19.26 ± 7.79 ng h/ml; peak plasma concentration (C max) 1.18 ± 0.37 ng/ml; time to C max (T max) 5.38 ± 0.74 h; and elimination half-life (t 1/2) 11.35 ± 2.06 h. The developed method was successfully used to study the bioavailability of a low dose (8 mg) of loperamide hydrochloride.

Original languageEnglish
Pages (from-to)421-427
Number of pages7
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume36
Issue number2
DOIs
Publication statusPublished - 2004 Oct 29

Fingerprint

Loperamide
Biological Availability
Capsules
Oral Administration
Volunteers
formic acid
Plasmas
Plasma (human)
Therapeutic Equivalency
Ketoconazole
Pharmacokinetics
Mass spectrometers
Area Under Curve
Half-Life
Assays
Healthy Volunteers
Water
Monitoring

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry
  • Pharmaceutical Science
  • Drug Discovery
  • Spectroscopy
  • Clinical Biochemistry

Cite this

@article{7a27a4db32e049f893bba8c9051e8003,
title = "LC-MS determination and bioavailability study of loperamide hydrochloride after oral administration of loperamide capsule in human volunteers",
abstract = "The purpose of the present study was to develop a standard protocol for loperamide hydrochloride bioequivalence testing. For this purpose, a simple rapid and selective LC-MS method utilizing a single quadrupole mass spectrometer was developed and validated for the determination of loperamide hydrochloride in human plasma, and we followed this with a bioavailability study. Methyl tert-butylether (MTBE) was used to extract loperamide hydrochloride and ketoconazole (internal standard (IS)) from an alkaline plasma sample. LC separation was performed on a Zorbax RX C 18 column (5 μm, 2.1 mm × 150 mm) using acetonitrile-water-formic acid (50:50:0.1 (v/v)) as a mobile phase. The retention times of loperamide hydrochloride and IS were 1.2 and 0.8 min, respectively. Quadrupole MS detection was by monitoring at m/z 477 (M + 1) corresponding to loperamide hydrochloride and at m/z 531 (M + 1) for IS. The described assay method showed acceptable precision, accuracy, linearity, stability, and specificity. The bioavailability of loperamide hydrochloride was evaluated in eight healthy male volunteers. The following pharmacokinetic parameters were elucidated after administering a single dose of four 2 mg capsules of loperamide: the area under the plasma concentration versus time curve from time 0 to 72 h (AUC 72 h) 19.26 ± 7.79 ng h/ml; peak plasma concentration (C max) 1.18 ± 0.37 ng/ml; time to C max (T max) 5.38 ± 0.74 h; and elimination half-life (t 1/2) 11.35 ± 2.06 h. The developed method was successfully used to study the bioavailability of a low dose (8 mg) of loperamide hydrochloride.",
author = "Yu, {Jin Hee} and Kim, {Hye Jin} and Sibeum Lee and Hwang, {Sung Joo} and Won Kim and Moon, {Cheol Jin}",
year = "2004",
month = "10",
day = "29",
doi = "10.1016/j.jpba.2004.06.020",
language = "English",
volume = "36",
pages = "421--427",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",
number = "2",

}

LC-MS determination and bioavailability study of loperamide hydrochloride after oral administration of loperamide capsule in human volunteers. / Yu, Jin Hee; Kim, Hye Jin; Lee, Sibeum; Hwang, Sung Joo; Kim, Won; Moon, Cheol Jin.

In: Journal of Pharmaceutical and Biomedical Analysis, Vol. 36, No. 2, 29.10.2004, p. 421-427.

Research output: Contribution to journalArticle

TY - JOUR

T1 - LC-MS determination and bioavailability study of loperamide hydrochloride after oral administration of loperamide capsule in human volunteers

AU - Yu, Jin Hee

AU - Kim, Hye Jin

AU - Lee, Sibeum

AU - Hwang, Sung Joo

AU - Kim, Won

AU - Moon, Cheol Jin

PY - 2004/10/29

Y1 - 2004/10/29

N2 - The purpose of the present study was to develop a standard protocol for loperamide hydrochloride bioequivalence testing. For this purpose, a simple rapid and selective LC-MS method utilizing a single quadrupole mass spectrometer was developed and validated for the determination of loperamide hydrochloride in human plasma, and we followed this with a bioavailability study. Methyl tert-butylether (MTBE) was used to extract loperamide hydrochloride and ketoconazole (internal standard (IS)) from an alkaline plasma sample. LC separation was performed on a Zorbax RX C 18 column (5 μm, 2.1 mm × 150 mm) using acetonitrile-water-formic acid (50:50:0.1 (v/v)) as a mobile phase. The retention times of loperamide hydrochloride and IS were 1.2 and 0.8 min, respectively. Quadrupole MS detection was by monitoring at m/z 477 (M + 1) corresponding to loperamide hydrochloride and at m/z 531 (M + 1) for IS. The described assay method showed acceptable precision, accuracy, linearity, stability, and specificity. The bioavailability of loperamide hydrochloride was evaluated in eight healthy male volunteers. The following pharmacokinetic parameters were elucidated after administering a single dose of four 2 mg capsules of loperamide: the area under the plasma concentration versus time curve from time 0 to 72 h (AUC 72 h) 19.26 ± 7.79 ng h/ml; peak plasma concentration (C max) 1.18 ± 0.37 ng/ml; time to C max (T max) 5.38 ± 0.74 h; and elimination half-life (t 1/2) 11.35 ± 2.06 h. The developed method was successfully used to study the bioavailability of a low dose (8 mg) of loperamide hydrochloride.

AB - The purpose of the present study was to develop a standard protocol for loperamide hydrochloride bioequivalence testing. For this purpose, a simple rapid and selective LC-MS method utilizing a single quadrupole mass spectrometer was developed and validated for the determination of loperamide hydrochloride in human plasma, and we followed this with a bioavailability study. Methyl tert-butylether (MTBE) was used to extract loperamide hydrochloride and ketoconazole (internal standard (IS)) from an alkaline plasma sample. LC separation was performed on a Zorbax RX C 18 column (5 μm, 2.1 mm × 150 mm) using acetonitrile-water-formic acid (50:50:0.1 (v/v)) as a mobile phase. The retention times of loperamide hydrochloride and IS were 1.2 and 0.8 min, respectively. Quadrupole MS detection was by monitoring at m/z 477 (M + 1) corresponding to loperamide hydrochloride and at m/z 531 (M + 1) for IS. The described assay method showed acceptable precision, accuracy, linearity, stability, and specificity. The bioavailability of loperamide hydrochloride was evaluated in eight healthy male volunteers. The following pharmacokinetic parameters were elucidated after administering a single dose of four 2 mg capsules of loperamide: the area under the plasma concentration versus time curve from time 0 to 72 h (AUC 72 h) 19.26 ± 7.79 ng h/ml; peak plasma concentration (C max) 1.18 ± 0.37 ng/ml; time to C max (T max) 5.38 ± 0.74 h; and elimination half-life (t 1/2) 11.35 ± 2.06 h. The developed method was successfully used to study the bioavailability of a low dose (8 mg) of loperamide hydrochloride.

UR - http://www.scopus.com/inward/record.url?scp=5644291083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5644291083&partnerID=8YFLogxK

U2 - 10.1016/j.jpba.2004.06.020

DO - 10.1016/j.jpba.2004.06.020

M3 - Article

VL - 36

SP - 421

EP - 427

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

IS - 2

ER -